AI-generated summary
The authors studied 11 patients with major depressive disorder who received 820 nm transcranial photobiomodulation targeting the left frontal pole for 14 days. They report that symptom scale scores decreased significantly and stayed lower at 8-week follow-up, and that brain network connectivity in patients moved closer to healthy controls. The study was a small pilot without a control group.
- Participants
- 11
- Who or what was studied
- 11 patients with major depressive disorder; five healthy controls and five patients underwent TMS-EEG
- Wavelengths
- 820 nm
- Limits stated in the abstract
- The abstract describes a small pilot study with no control group of treated patients, so the findings cannot establish efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 820 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Electroencephalography, Transcranial magnetic stimulation, Photobiomodulation, Pilot study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.